Big Pharma-backed Sitryx Locks an Additional $39M in a Series A Raise to Advance its Immunometabolic Pipeline September 28, 2023
Sitryx Raises Additional $39 Million to Progress Development of Disease-modifying Therapeutics for Chronic AutoImmune and Inflammatory Disease September 27, 2023
Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism September 26, 2023
Phil Vickers talks new role as head of Longwood’s Solu after Faze shutdown; Regeneron CFO to retire in February September 15, 2023
Lassen Therapeutics Presents New Data on LASN01 for the Treatment of Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease September 12, 2023
Solu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive Officer September 11, 2023
